OBJECTIVE: To describe changes in immune activation and reconstitution markers among HIV-1-infected patients receiving antiretroviral therapy (ART) in Abidjan, Côte d'Ivoire. METHODS: Between November 1998 and February 2001, we analyzed changes in immune activation and reconstitution markers among 52 patients. Good virologic responders (n = 26) were defined as those who had suppressed and maintained plasma viral load (VL) below the detection limit of the assay for at least 12 months. Poor virologic responders (n = 26) were defined as those with a detectable VL at 6 and 12 months after beginning ART. RESULTS: Of the 26 good virologic responders, 20 (77%) were on highly active antiretroviral therapy (HAART) compared with one (4%) of the poor responders. Among the 26 good responders, baseline median levels of CD38+CD8+ T cells were elevated, but had decreased significantly at 6 months (P < 0.001) and at 12 months of therapy (P < 0.001). Median levels of HLA-DR+CD8+ T cells also decreased from baseline at 6 months (P < 0.001) and at 12 months of therapy (P < 0.001). Levels of CD62L+CD4+ T cells increased steadily during the 6 and 12 months of therapy and reached levels observed among HIV-negative blood donors (P = 0.07). Among the 26 poor responders, median levels of CD38+CD8+ T cells decreased significantly at 12 months of therapy (P = 0.006), but were higher than levels in blood donors (P = 0.005). Levels of HLA-DR+CD8+ T cells decreased significantly at 12 months of therapy (P < 0.001). Levels of CD62L+CD4+ decreased over time. CONCLUSION: Our results suggest that HAART can be successfully used in African populations with elevated baseline immune activation markers.
OBJECTIVE: To describe changes in immune activation and reconstitution markers among HIV-1-infectedpatients receiving antiretroviral therapy (ART) in Abidjan, Côte d'Ivoire. METHODS: Between November 1998 and February 2001, we analyzed changes in immune activation and reconstitution markers among 52 patients. Good virologic responders (n = 26) were defined as those who had suppressed and maintained plasma viral load (VL) below the detection limit of the assay for at least 12 months. Poor virologic responders (n = 26) were defined as those with a detectable VL at 6 and 12 months after beginning ART. RESULTS: Of the 26 good virologic responders, 20 (77%) were on highly active antiretroviral therapy (HAART) compared with one (4%) of the poor responders. Among the 26 good responders, baseline median levels of CD38+CD8+ T cells were elevated, but had decreased significantly at 6 months (P < 0.001) and at 12 months of therapy (P < 0.001). Median levels of HLA-DR+CD8+ T cells also decreased from baseline at 6 months (P < 0.001) and at 12 months of therapy (P < 0.001). Levels of CD62L+CD4+ T cells increased steadily during the 6 and 12 months of therapy and reached levels observed among HIV-negative blood donors (P = 0.07). Among the 26 poor responders, median levels of CD38+CD8+ T cells decreased significantly at 12 months of therapy (P = 0.006), but were higher than levels in blood donors (P = 0.005). Levels of HLA-DR+CD8+ T cells decreased significantly at 12 months of therapy (P < 0.001). Levels of CD62L+CD4+ decreased over time. CONCLUSION: Our results suggest that HAART can be successfully used in African populations with elevated baseline immune activation markers.
Authors: Michael A Eller; Marc S Opollo; Michelle Liu; Andrew D Redd; Leigh Anne Eller; Cissy Kityo; Joshua Kayiwa; Oliver Laeyendecker; Maria J Wawer; Mark Milazzo; Noah Kiwanuka; Ronald H Gray; David Serwadda; Nelson K Sewankambo; Thomas C Quinn; Nelson L Michael; Fred Wabwire-Mangen; Johan K Sandberg; Merlin L Robb Journal: J Infect Dis Date: 2014-11-17 Impact factor: 5.226
Authors: Elijah M Songok; Ma Luo; Ben Liang; Paul Mclaren; Nadine Kaefer; Winnie Apidi; Genevieve Boucher; Joshua Kimani; Charles Wachihi; Rafick Sekaly; Keith Fowke; Blake T Ball; Francis A Plummer Journal: PLoS One Date: 2012-01-26 Impact factor: 3.240
Authors: Ramy El-Diwany; Florian P Breitwieser; Mary Soliman; Alyza M Skaist; Geetha Srikrishna; Joel N Blankson; Stuart C Ray; Sarah J Wheelan; David L Thomas; Ashwin Balagopal Journal: AIDS Date: 2017-06-19 Impact factor: 4.177
Authors: A S Walker; D Ford; C F Gilks; P Munderi; F Ssali; A Reid; E Katabira; H Grosskurth; P Mugyenyi; J Hakim; J H Darbyshire; D M Gibb; A G Babiker Journal: Lancet Date: 2010-03-27 Impact factor: 79.321
Authors: Livio Azzoni; Nigel J Crowther; Cynthia Firnhaber; Andrea S Foulkes; Xiangfan Yin; Deborah Glencross; Robert Gross; Mitch D Kaplan; Emmanouil Papasavvas; Doreen Schulze; Wendy Stevens; Tessa van der Merwe; Rita Waisberg; Ian Sanne; Luis J Montaner Journal: J Int AIDS Soc Date: 2010-09-07 Impact factor: 5.396
Authors: Brett D Shepard; Mona R Loutfy; Janet Raboud; Frank Mandy; Colin M Kovacs; Christina Diong; Michele Bergeron; Victoria Govan; Stacey A Rizza; Jonathan B Angel; Andrew D Badley Journal: J Acquir Immune Defic Syndr Date: 2008-06-01 Impact factor: 3.731
Authors: Fabrice Tiba; Frans Nauwelaers; Siaka Traoré; Boubacar Coulibaly; Thierry Ouedraogo; Adama Compaoré; Hans-Georg Kräusslich; Thomas Böhler Journal: Open AIDS J Date: 2012-02-24
Authors: Jembia J Mosoko; Wilfred Akam; Paul J Weidle; John T Brooks; Asabi J Aweh; Thompson N Kinge; Sherri Pals; Pratima L Raghunathan Journal: J Int AIDS Soc Date: 2011-06-16 Impact factor: 5.396